Aripiprazole (Abilify) not approved for bipolar disorder
According to a press release, the Scottish Medicines Consortium (SMC) did not accept aripiprazole for the treatment of manic episodes in bipolar I disorder and for the prevention of new manic episodes. According to the SMC, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance. Psychiatrist Daniel Carlat from “The Carlat […]
Aripiprazole IM (Abilify) for agitation control in patients with schizophrenia: SMC review
The Scottish Medicines Consortium issued on 7th December, 2008 an advice on the aripiprazole intramuscular injection (Abilify): Aripiprazole intramuscular injection (Abilify ) is accepted for use in NHS Scotland for the rapid control of agitation and disturbed behaviours in patients with schizophrenia when oral therapy is not appropriate.